Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
RESEARCH TOOLSreports
Holding TRDA?
Track your performance easily
TRDA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.35 - $20.49
Previous Close$19.89
Volume78.39K
Average Volume (3M)134.61K
Market Cap
$744.28M
Enterprise Value$727.55M
Total Cash (Recent Filing)$78.05M
Total Debt (Recent Filing)$61.31M
Price to Earnings (P/E)12.5
Beta1.15
Next Earnings
Mar 12, 2025EPS Estimate
-$0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding37,419,975
10 Day Avg. Volume164,341
30 Day Avg. Volume134,612
Standard Deviation0.24
R-Squared0.00293
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.59
Price to Sales (P/S)3.09
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit5.64
Enterprise Value/Ebitda9.90
Forecast
1Y Price Target
$24.00Price Target Upside20.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Entrada Therapeutics Inc News
PremiumCompany Announcements
Entrada Therapeutics’ Q3 2024 Financial Highlights
PremiumPre-Earnings
Is TRDA a Buy, Before Earnings?
Ownership Overview
17.17% Insiders
14.61% Mutual Funds
42.34% Other Institutional Investors
18.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRDA FAQ
What was Entrada Therapeutics Inc’s price range in the past 12 months?
Entrada Therapeutics Inc lowest stock price was $11.35 and its highest was $20.49 in the past 12 months.
What is Entrada Therapeutics Inc’s market cap?
Currently, no data Available
When is Entrada Therapeutics Inc’s upcoming earnings report date?
Entrada Therapeutics Inc’s upcoming earnings report date is Mar 12, 2025 which is in 87 days.
How were Entrada Therapeutics Inc’s earnings last quarter?
Entrada Therapeutics Inc released its earnings results on Nov 05, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.728 by $0.378.
Is Entrada Therapeutics Inc overvalued?
According to Wall Street analysts Entrada Therapeutics Inc’s price is currently Undervalued.
Does Entrada Therapeutics Inc pay dividends?
Entrada Therapeutics Inc does not currently pay dividends.
What is Entrada Therapeutics Inc’s EPS estimate?
Entrada Therapeutics Inc’s EPS estimate is -$0.68.
How many shares outstanding does Entrada Therapeutics Inc have?
Entrada Therapeutics Inc has 37,419,975 shares outstanding.
What happened to Entrada Therapeutics Inc’s price movement after its last earnings report?
Entrada Therapeutics Inc reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.728. Following the earnings report the stock price went up 4.783%.
Which hedge fund is a major shareholder of Entrada Therapeutics Inc?
Among the largest hedge funds holding Entrada Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Entrada Therapeutics Inc’s shares valued at 78M.
---
Entrada Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (20.66% Upside)
$24.00 (20.66% Upside)
Hedge Fund Trend
Increased
By 70.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 15.1%
Last 30 Days ▼ 15.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.76%
12-Months-Change
Fundamentals
Return on Equity
16.43%
Trailing 12-Months
Asset Growth
14.34%
Trailing 12-Months
Company Description
Entrada Therapeutics Inc
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
---
TRDA Stock 12 Month Forecast
Average Price Target
$24.00
▲(20.66% Upside)
Technical Analysis
Best Analysts Covering TRDA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+25.43%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +25.43% per trade.
---